Glenmark Pharmaceuticals Sees 13.9% Surge in Open Interest to 36,686 Contracts

Glenmark Pharmaceuticals Ltd. has experienced a significant increase in open interest today, reflecting notable activity in the stock. The latest open interest stands at 36,686, up from the previous figure of 32,209, marking a change of 4,477, or 13.9%. This uptick in open interest coincides with a trading volume of 18,585, indicating heightened market engagement.
In terms of performance, Glenmark Pharmaceuticals has outperformed its sector by 0.44%, with a 1D return of 0.38%. The stock has shown consistent gains over the past two days, accumulating a total return of 0.55% during this period. While the stock is currently trading above its 200-day moving average, it remains below the 5-day, 20-day, 50-day, and 100-day moving averages.

Despite this positive performance, there has been a notable decline in investor participation, with delivery volume on October 21 dropping by 92.45% compared to the 5-day average. The stock maintains sufficient liquidity for trading, with a market cap of Rs 52,559.90 crore, categorizing it as a mid-cap stock. Overall, the increase in open interest highlights a dynamic trading environment for Glenmark Pharmaceuticals.